Nowadays, genetic modification with T-cell receptors (TCRs) specific for AFP can potentially redirect TCR-gene-engineered human T cells to specifically recognize and then kill HCC tumor cells [118,119,120]. This evidence concerns the gene AFP and hepatocellular carcinoma.